Drug Profile


Alternative Names: Anti-CD4 monoclonal antibody IDEC 151; IDEC 151; Lenoliximab; PRIMATIZED anti-CD4 antibody IDEC 151; SB 217969

Latest Information Update: 10 Aug 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biogen Idec
  • Class Monoclonal antibodies
  • Mechanism of Action CD4 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 10 Aug 2006 Discontinued - Phase-II for Rheumatoid arthritis in United Kingdom (unspecified route)
  • 10 Aug 2006 Discontinued - Phase-II for Rheumatoid arthritis in USA (unspecified route)
  • 17 Nov 2003 IDEC Pharmaceuticals has merged with Biogen to form Biogen Idec
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top